HCAT Health Catalyst, Inc.
Services-Computer Programming, Data Processing, Etc. · Nasdaq · SEC CIK 1636422 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-13.9%
TTM net income YoY-87.8%
TTM EPS YoY-77.2%
Revenue 3-yr CAGR-2.1%
Net income 3-yr CAGR—
Margins
Gross margin49.1%
Operating margin-65.7%
Net margin-74.2%
FCF margin9.4%
EBITDA margin-48.9%
Returns
ROE-84.6%
ROA-49.0%
ROIC (approx.)-52.7%
Asset turnover0.66x
Leverage & solvency
Liabilities / assets38.7%
Debt / equity0.00x
Current ratio1.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.13x
Accruals ratio-55.5%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $311.14M | $306.58M |
| Cost of revenue | $159.46M | $165.81M |
| Gross profit | $151.68M | $140.78M |
| R&D expense | $49.77M | $57.95M |
| SG&A expense | $49.56M | $56.82M |
| Operating income | -$160.85M | -$69.81M |
| Pretax income | -$177.26M | -$69.17M |
| Income tax | $716,000 | $333,000 |
| Net income | -$177.97M | -$69.50M |
| EBITDA | -$110.35M | -$28.38M |
| EPS (basic) | -2.55 | -1.15 |
| EPS (diluted) | -2.55 | -1.15 |
| Weighted avg. shares (diluted) | 69.90M | 60.18M |
| Balance sheet | ||
| Cash & equivalents | $50.81M | $249.65M |
| Short-term investments | $44.92M | $142.35M |
| Receivables | $59.13M | $57.18M |
| Current assets | $169.31M | $465.65M |
| PP&E, net | $33.84M | $29.39M |
| Goodwill | $209.07M | $259.76M |
| Intangibles | $77.68M | $86.05M |
| Total assets | $502.64M | $858.93M |
| Current liabilities | $89.57M | $325.85M |
| Short-term debt | $1.63M | $231.18M |
| Long-term debt | $151.62M | $151.18M |
| Total debt | $153.25M | $382.36M |
| Total liabilities | $256.86M | $493.72M |
| Shareholders' equity | $245.78M | $365.21M |
| Net debt | $102.44M | $132.72M |
| Shares outstanding | 72.03M | 64.04M |
| Cash flow statement | ||
| Operating cash flow | $731,000 | $14.56M |
| Capital expenditure | $968,000 | $1.62M |
| Free cash flow | -$237,000 | $12.94M |
| Investing cash flow | $36.19M | -$22.90M |
| Financing cash flow | -$235.78M | $151.75M |
| Depreciation & amortization | $50.50M | $41.43M |
| Stock-based compensation | $27.01M | $40.13M |
| Share buybacks | $5.00M | $0 |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.